hgh injections for sale usa
The first reports of human experiments involving high-dose hgh injections were reported to the U.S. Food and Drug Administration (FDA) in 1965. From 1971 to 1976, six cases of high-dose hgh injections, with at least three infants showing signs of toxicity, were documented to the FDA. In the first three cases, the hgh injections were administered by major hospital clinics. No report has surfaced in recent years in which infants with certain abnormalities are injected with high doses of hgh. Because of high infant mortality rates resulting from congenital abnormalities and complications such as pregnancy loss and birth defects, the medical establishment routinely declines to take the risk of delivering any child with certain severe abnormalities to a pregnancy. But because hgh injections for sale usa are currently for sale in the United States, the medical establishment is obliged to monitor the safety of all drugs that are used for treating humans, and so they report that a clinical trial has been completed on high-dose hgh injections. A group of practitioners specializing in the treatment of sickle-cell disease—a chronic disease in which the sickle cells grow in the blood, forming sickles which attach to the wall of blood vessels, blocking blood flow and creating blockages—undertook a clinical trial of high-dose hgh injections in the United States. The trial was approved by an FDA committee that reviews all clinical trials submitted to the FDA. Each doctor who participated in the clinical trial injected a single patient for one year. A similar trial was conducted by other hgh injection practitioners in Europe. A major manufacturer of hgh injections, Hemophila, is a subsidiary of the American pharmaceutical company Searle. The manufacturer announced in 1975 that it was planning to submit a drug application to the FDA to sell high-dose hgh injections, and one of its officials said that trials of high-
